Pfizer closed the third quarter of 2026 with an attributed net profit of $3.242 billion (€2.896 billion), representing an 8% decline compared with the same period of the previous year, a drop linked mainly to the effect of atypical items, as the multinational reported, which at the same time has revised upward its annual projections.
Between July and September, the accounts of the pharmaceutical giant recorded an extraordinary negative impact of $791 million (€707 million) due to restructuring costs, clearly above the $286 million (€255 million) registered one year earlier for this same concept.
The company’s revenue in the third quarter stood at $16.583 billion (€14.813 billion), 0.4% below the level reached in the same stretch of 2025. However, accumulated income through September totaled $46.067 billion (€41.150 billion), which represents an increase of 2.3% compared with the first three quarters of the previous fiscal year.
In the first nine months of the year, Pfizer’s net profit fell 40% year-on-year, to $5.681 billion (€5.075 billion), held back by a greater adverse impact from restructuring costs, which totaled $1.347 billion (€1.203 billion), 42.5% more. In addition, the laboratory recorded net deductions or charges of $4.866 billion (€4.347 billion), which include legal matters and amortizations.
"Pfizer had another strong quarter, with a strong commercial boost and disciplined execution, while we made progress in our strategy to create long-term value for shareholders," said Albert Bourla, Chairman and Chief Executive Officer of Pfizer, who highlighted advances in the company’s obesity program and the latest milestones achieved in oncology, immunology, and vaccines.
"With a solid set of expected catalysts, I believe we are well positioned to deliver new meaningful medicines for patients and enduring value in the coming years," he added.
The company’s chief financial officer, Cecille Guegan, said that the results of the third quarter show robust commercial performance on a global scale and sustained operational discipline. In her view, this allows Pfizer to raise its guidance for revenue and adjusted diluted earnings per share for the full year of 2026, "which reflects strong performance year to date and confidence in our business."
After the review, the pharmaceutical company now expects its annual sales to fall within a range of between $62.000 billion and $64.000 billion (55.382 and 57.168 million euros), above the previous range of $60.500 billion to $62.500 billion (54.042 and 55.829 million euros). Likewise, adjusted diluted earnings per share is estimated to be between $2.95 and $3.05, improving on the prior forecast, which ranged between $2.80 and $3.